V2 sact_regimen
781,388 rows · 12 columns
| ENCORE_PATIENT_ID | MERGED_REGIMEN_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | BENCHMARK_GROUP | LINK_NUMBER |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 160016741 | 160008303 | 1.68 | 76.1 | Neo-adjuvant (N) | 2016-04-06 | 2016-04-23 | EURO-EWING | 02 | N | DOXORUBICIN + OLARATUMAB | 101717234 |
| 160016743 | 160008304 | 0 | 0 | Palliative (P) | 2019-04-26 | 2019-04-27 | Doxorubicin + Olaratumab | 02 | N | TRIAL UNSPECIFIED | 101022985 |
| 160016744 | 160008305 | 1.56 | 70.1 | Neo-adjuvant (N) | 2018-09-24 | 2018-09-25 | Carboplatin AUC 6 - 10 | 02 | N | CARBOPLATIN | 101256662 |
| 160016745 | 160008306 | 1.75 | 103 | Palliative (P) | 2020-01-08 | 2020-01-17 | EW EuroEwing 2012 Arm B VDC | 02 | N | DOXORUBICIN + IFOSFAMIDE | 101560703 |
| 160016746 | 160008307 | 1.56 | 73.55 | Neo-adjuvant (N) | 2019-06-28 | 2019-07-01 | Carboplatin + Paclitaxel (weekly) | N | null | CARBOPLATIN + PACLITAXEL | 101457788 |
| 160016747 | 160008308 | null | null | Palliative (P) | 2017-02-01 | 2017-02-12 | Cisplatin + Pemetrexed | 01 | null | CISPLATIN + PEMETREXED | 100820783 |
| 160016749 | 160008309 | 1.95 | 87.3 | Palliative (P) | 2018-09-30 | 2018-10-14 | DOXORUBICIN + IFOSFAMIDE | 02 | N | LIPOSOMAL DOXORUBICIN | 100080250 |
| 160016750 | 160008310 | null | 54 | Adjuvant (A) | 2017-06-02 | 2017-06-26 | Carboplatin + Paclitaxel (3 weekly) | null | null | CARBOPLATIN + PACLITAXEL | 100610827 |
| 160016751 | 160008311 | 1.7 | 78.45 | Curative (C) | 2017-09-11 | 2017-09-26 | Carboplatin + Paclitaxel (3 weekly) | null | N | STS RHABDOMYOSARCOMA RMS 2005 IVAVV | 100201449 |
| 160016752 | 160008312 | 1.86 | 51.65 | null | 2017-09-10 | 2017-09-24 | STS Non-Rhabdo EpSSG 2005 Ifos Dox | 02 | null | LIPOSOMAL DOXORUBICIN | 101614131 |
| 160016754 | 160008313 | 1.73 | 78.8 | 03 | 2018-11-14 | 2018-12-05 | Trial Unspecified | 02 | N | ABIRATERONE | 100005003 |
| 160016755 | 160008314 | 0 | 55.6 | Palliative (P) | 2017-10-04 | 2017-10-04 | DOXORUBICIN | 02 | N | DOXORUBICIN + IFOSFAMIDE | 100049426 |
| 160016758 | 160008315 | 1.72 | 80 | Palliative (P) | null | 2012-05-14 | Doxorubicin + Ifosfamide | Y | N | VINORELBINE | 100457650 |
| 160016759 | 160008316 | 1.64 | 87.7 | Palliative (P) | 2018-12-31 | 2019-01-09 | Bevacizumab 7.5mg/kg | 02 | N | TRIAL UNSPECIFIED | 100116530 |
| 160016764 | 160008317 | null | null | Palliative (P) | null | 2021-01-22 | Doxorubicin + Olaratumab | N | null | CYCLOPHOSPHAMIDE + DOCETAXEL | 100113762 |
| 160016771 | 160008318 | 0 | 55.6 | Palliative (P) | 2020-08-18 | 2020-08-18 | Sunitinib | null | N | MELPHALAN | 101105237 |
| 160016774 | 160008319 | 1.76 | 73.35 | Palliative (P) | 2019-10-19 | 2019-11-12 | CHLORAMBUCIL + RITUXIMAB | N | null | CISPLATIN + PACLITAXEL | 100382489 |
| 160016777 | 160008320 | 1.68 | 59 | Palliative (P) | 2016-09-24 | 2019-12-30 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101479368 |
| 160016779 | 160008321 | 1.7 | 83.7 | Neo-adjuvant (N) | 2017-02-03 | 2017-03-14 | Doxorubicin 75mg/m2 | 02 | N | DOXORUBICIN | 100909788 |
| 160016780 | 160008322 | 1.78 | 86 | Curative (C) | 2016-03-24 | 2016-04-14 | Ipilimumab | 02 | N | LIPOSOMAL DOXORUBICIN | 100363669 |
| 160016781 | 160008323 | 1.66 | 97.8 | Palliative (P) | 2019-06-30 | 2019-07-04 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 101161125 |
| 160016782 | 160008324 | 1.7 | 81 | Palliative (P) | 2018-05-08 | 2018-05-08 | CARBOPLATIN + PACLITAXEL | 02 | N | CARBOPLATIN + PACLITAXEL | 100824888 |
| 160016783 | 160008325 | 1.62 | 79.7 | Palliative (P) | null | 2019-08-25 | Carboplatin + Paclitaxel (weekly) | Y | N | CARBOPLATIN + PACLITAXEL | 100415258 |
| 160016784 | 160008326 | 1.62 | 65.2 | null | null | null | Carboplatin AUC 6 - 10 | N | null | CARBOPLATIN | 101548082 |
| 160016787 | 160008327 | 0.6 | 57.6 | Palliative (P) | 2019-02-04 | 2019-02-10 | Doxorubicin + Ifosfamide | 01 | Y | EURO-EWING | 100011208 |
| 160016789 | 160008328 | 1.8 | 67 | Palliative (P) | 2021-02-22 | 2021-03-01 | Trial Unspecified | 02 | N | CARBOPLATIN + PACLITAXEL | 100641186 |
| 160016790 | 160008329 | 1.49 | 78 | Palliative (P) | 2016-02-28 | 2016-03-13 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 101687279 |
| 160016792 | 160008330 | 1.67 | 68.2 | Curative (C) | 2016-06-01 | 2016-06-02 | Paclitaxel 80mg/m2 day 1 8 15 | null | N | TRABECTEDIN | 101416809 |
| 160016795 | 160008331 | 0 | 113 | Palliative (P) | 2017-06-03 | 2017-06-17 | Abiraterone | 02 | N | ECX | 100985487 |
| 160016796 | 160008332 | 1.74 | 100 | Palliative (P) | 2019-02-23 | 2019-03-01 | Doxorubicin + Ifosfamide | N | N | ETOPOSIDE + IFOSFAMIDE | 101456359 |
| 160016802 | 160008333 | 1.56 | 69.5 | Neo-adjuvant (N) | 2018-03-14 | 2018-03-19 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 101818931 |
| 160016803 | 160008334 | 1.58 | 63.4 | 03 | 2018-09-04 | 2018-09-19 | CARBOPLATIN | 02 | N | CARBOPLATIN | 101513425 |
| 160016804 | 160008335 | 1.63 | 74.2 | Palliative (P) | 2020-11-19 | 2020-12-02 | Doxorubicin + Ifosfamide | null | N | DOXORUBICIN + OLARATUMAB | 100358048 |
| 160016808 | 160008337 | 1.69 | 84.6 | Palliative (P) | 2019-02-27 | 2019-03-12 | STS Rhabdomyosarcoma RMS 2005 IVAVV | 02 | N | LIPOSOMAL DOXORUBICIN | 101382768 |
| 160016809 | 160008338 | null | null | Neo-adjuvant (N) | 2019-04-03 | 2019-04-05 | Cisplatin + Pemetrexed | 02 | null | CISPLATIN + PEMETREXED | 100670122 |
| 160016810 | 160008339 | 1.63 | 68 | Curative (C) | 2017-11-04 | 2017-11-18 | DOXORUBICIN | 02 | N | DOXORUBICIN | 101402124 |
| 160016811 | 160008340 | 1.68 | 82.9 | Palliative (P) | null | null | PACLITAXEL | N | N | NB HRNBL-1 COJEC IND COURSE B | 100428216 |
| 160016817 | 160008341 | 1.79 | 94.2 | Palliative (P) | 2018-06-21 | 2018-06-23 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101350832 |
| 160016818 | 160008342 | 1.79 | 74.2 | Palliative (P) | 2018-08-04 | 2018-09-12 | NB Low/Interm risk guidelines Carbo/Etop | null | N | CARBOPLATIN + PACLITAXEL | 100881694 |
| 160016819 | 160008343 | null | 13.25 | Adjuvant (A) | 2017-04-18 | 2017-04-19 | BEP 3 day | 02 | null | PEMBROLIZUMAB | 101758856 |
| 160016821 | 160008344 | null | 123.8 | null | null | 2020-08-03 | Carboplatin AUC 2 - 5 | 02 | N | CARBOPLATIN | 100993875 |
| 160016822 | 160008345 | 1.79 | 82 | Neo-adjuvant (N) | 2018-12-16 | 2018-12-16 | Cisplatin + Pemetrexed | 02 | N | CISPLATIN + PEMETREXED | 100360392 |
| 160016825 | 160008346 | 1.75 | 99.5 | null | 2019-08-22 | 2019-08-24 | Trial Unspecified | 02 | N | DOXORUBICIN + OLARATUMAB | 101577840 |
| 160016826 | 160008347 | 1.66 | 89 | Palliative (P) | 2019-05-05 | 2019-05-05 | Carboplatin + Paclitaxel (3 weekly) | 02 | N | CARBOPLATIN + PACLITAXEL | 101137397 |
| 160016827 | 160008348 | 1.6 | 55.2 | 03 | 2018-05-14 | 2018-05-22 | ICON8B TRIAL | 1 | N | VIDE | 100174492 |
| 160016830 | 160008349 | 1.72 | 79.5 | Palliative (P) | 2019-07-17 | 2019-07-18 | Doxorubicin + Olaratumab | 02 | N | VIDE | 101372821 |
| 160016833 | 160008350 | 1.61 | 43 | Palliative (P) | 2016-10-06 | 2016-10-16 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 100285960 |
| 160016834 | 160008351 | 1.62 | 71.7 | Palliative (P) | 2016-12-07 | 2016-12-08 | MELPHALAN | N | N | IMATINIB | 101549790 |
| 160016836 | 160008352 | 1.75 | 93.5 | Palliative (P) | 2018-10-18 | 2018-10-18 | Cisplatin + Pemetrexed | N | N | CISPLATIN + PEMETREXED | 101716791 |
| 160016837 | 160008353 | 1.76 | 97.4 | Palliative (P) | 2020-04-18 | 2020-04-25 | Doxorubicin + Ifosfamide | 01 | null | GEMCARBO | 101115635 |